Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Arch Bronconeumol ; 57: 97, 2021 Jan.
Article in English | MEDLINE | ID: covidwho-885199
2.
Am J Transplant ; 21(4): 1629-1632, 2021 04.
Article in English | MEDLINE | ID: covidwho-852163

ABSTRACT

To date, little is known about the duration and effectiveness of immunity as well as possible adverse late effects after an infection with SARS-CoV-2. Thus it is unclear, when and if liver transplantation can be safely offered to patients who suffered from COVID-19. Here, we report on a successful liver transplantation shortly after convalescence from COVID-19 with subsequent partial seroreversion as well as recurrence and prolonged shedding of viral RNA.


Subject(s)
Antibodies, Viral/blood , COVID-19/complications , End Stage Liver Disease/surgery , Liver Transplantation , Virus Shedding , COVID-19/pathology , Humans , Male , Middle Aged , RNA, Viral/genetics , SARS-CoV-2 , Severity of Illness Index
3.
Clin Transplant ; 34(10): e14027, 2020 10.
Article in English | MEDLINE | ID: covidwho-615069

ABSTRACT

Immunosuppression leaves transplanted patients at particular risk for severe acute respiratory syndrome 2 (SARS-CoV-2) infection. The specific features of coronavirus disease 2019 (COVID-19) in immunosuppressed patients are largely unknown and therapeutic experience is lacking. Seven transplanted patients (two liver, three kidneys, one double lung, one heart) admitted to the Ludwig-Maximilians-University Munich because of COVID-19 and tested positive for SARS-CoV-2 were included. The clinical course and the clinical findings were extracted from the medical record. The two liver transplant patients and the heart transplant patient had an uncomplicated course and were discharged after 14, 18, and 12 days, respectively. Two kidney transplant recipients were intubated within 48 hours. One kidney and the lung transplant recipients were required to intubate after 10 and 15 days, respectively. Immunosuppression was adapted in five patients, but continued in all patients. Compared to non-transplanted patients at the ICU (n = 19) the inflammatory response was attenuated in transplanted patients, which was proven by decreased IL-6 blood values. This analysis might provide evidence that continuous immunosuppression is safe and probably beneficial since there was no hyperinflammation evident. Although transplanted patients might be more susceptible to an infection with SARS-CoV-2, their clinical course seems to be similar to immunocompetent patients.


Subject(s)
COVID-19/immunology , Graft Rejection/prevention & control , Immunocompromised Host , Immunosuppressive Agents/administration & dosage , Inflammation/immunology , Organ Transplantation , Postoperative Complications/immunology , Adolescent , Adult , Aged , Aged, 80 and over , COVID-19/diagnosis , COVID-19/therapy , COVID-19 Testing , Drug Administration Schedule , Female , Graft Rejection/immunology , Humans , Immunosuppressive Agents/therapeutic use , Inflammation/diagnosis , Inflammation/therapy , Inflammation/virology , Male , Middle Aged , Postoperative Complications/diagnosis , Postoperative Complications/therapy , Postoperative Complications/virology , Prognosis , Retrospective Studies , Severity of Illness Index , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...